Anticalins as an alternative to antibody technology

Bibliography

• FLOWER DR: The lipocalin protein family:structure and function. Biochem. J. (1996) 318:1–14.
   PubMed Web of Science ®Google Scholar
• SKERRA k Lipocalins as a scaffold. Biochim. Biophys. Acta (2000) 1482:337–350.
   Google Scholar
• BISHOP RE, WEINER JH: 'Outlier' lipocalins more than peripheral. Trends Biochem. Sci. (1996) 21:127.
   PubMed Web of Science ®Google Scholar
• NEWCOMER ME, JONES TA, AQVIST J et al.: The three-dimensional structure of retinol-binding protein. EMBO J. (1984) 3:1451–1454.
   PubMed Web of Science ®Google Scholar
• FLOWER DR: Multiple molecular recognition properties of the lipocalin protein family. J. MoL Recognit. (1995) 8:185–195.
   PubMed Web of Science ®Google Scholar
• COWAN S, NEWCOMER M, JONES T: Crystallographic refinement of human serum retinol binding protein at 2A resolution. Proteins (1990) 8:44–61.
   PubMed Web of Science ®Google Scholar
• BIANCHET MA, BAINS G, PELOSI P et al.: The three-dimensional structure of bovine odorant binding protein and its mechanism of odor recognition. Nat. Struct. Biol. (1996) 3:934–939.
   PubMedGoogle Scholar
• BOCSKEI Z, GROOM CR, FLOWER DR et al.: Pheromone binding to two rodent urinary proteins revealed by X-ray crystallography. Nature (1992) 360:186–188.
   PubMed Web of Science ®Google Scholar
• URADE Y, HAYAISHI O: Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim. Biophys. Acta (2000) 1482:259–271.
   PubMed Web of Science ®Google Scholar
• GOETZ DH, HOLMES MA, BORREGAARD N, BLUHM ME, RAYMOND KN, STRONG RK: The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell (2002) 10:1033–1043.
   PubMed Web of Science ®Google Scholar
• FLO TH, SMITH KD, SATO S et al.: Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature (2004) 432:917–921.
   PubMed Web of Science ®Google Scholar
• BREUSTEDT DA, KORNDORFER IP, REDL B, SKERRA A: The 1.8-A crystal structure of human tear lipocalin reveals an extended branched cavity with capacity for multiple ligands. J. Biol. Chem. (2005) 280:484–493.
   Google Scholar
• GLASGOW BJ, ABDURAGIMOV AR, FARAHBAKHSH ZT, FAULL KF, HUBBELL WL: Tear lipocalins bind a broad array of lipid ligands. Curr. Eye Res. (1995) 14:363–372.
   PubMed Web of Science ®Google Scholar
• REDL B: Human tear lipocalin. Biochim. Biophys. Acta (2000) 1482:241–248.
   PubMed Web of Science ®Google Scholar
• REDL B, HOLZFEIND P, LOTTSPEICH F: cDNA cloning and sequencing reveals human tear prealbumin to be a member of the lipophilic-ligand carrier protein superfamily. j Biol Chem. (1992) 267:20282–20287.
   PubMed Web of Science ®Google Scholar
• GASYMOV OK, ABDURAGIMOV AR, YUSIFOV TN, GLASGOW BJ: Relaxation of O-structure in tear lipocalin and enhancement of retinoid binding. Invest. Ophthalmol. Vis. Sci. (2002) 43:3165–3173.
   PubMed Web of Science ®Google Scholar
• LECHNER M, WOJNAR P, REDL B: Human tear lipocalin acts as an oxidative-stress-induced scavenger of potentially harmful lipid peroxidation products in a cell culture system. Biochem. J. (2001) 356:129–135.
   PubMed Web of Science ®Google Scholar
• FLUCKINGER M, HAAS H, MERSCHAK P, GLASGOW BJ, REDL B: Human tear lipocalin exhibits antimicrobial activity by scavenging microbial siderophores. Antimicrob. Agents Chemother. (2004) 48:3367–3372.
   PubMed Web of Science ®Google Scholar
• GASYMOV OK, ABDURAGIMOV AR,GASIMOV EO, YUSIFOV TN, DOOLEY AN, GLASGOW BJ: Tear lipocalin: potential for selective delivery of rifampin. Biochim. Biophys. Acta (2004) 1688:102–111.
   PubMed Web of Science ®Google Scholar
• QIN BY, BEWLEY MC, CREAMER LK, BAKER HM, BAKER EN, JAMESON GB: Structural basis of the Tanford transition of bovine O-lactoglobulin. Biochemistry (1998) 37:14014–14023.
   PubMed Web of Science ®Google Scholar
• GOETZ DH, WILLIE ST, ARMEN RS, BRATT T, BORREGAARD N, STRONG RK: Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry (2000) 39:1935–1941.
   PubMed Web of Science ®Google Scholar
• RASSART E, BEDIRIAN A, DO CARMO S et al.: Apolipoprotein D. Biochim. Biophys. Acta (2000) 1482:185–198.
   PubMed Web of Science ®Google Scholar
• VOGT M, SKERRA A: Bacterially produced apolipoprotein D binds progesterone and arachidonic acid, but not bilirubin or E-3M2H. j MoL Recognit. (2001) 14:79–86.
   PubMed Web of Science ®Google Scholar
• SCHINDLER PA, SETTINERI CA, COLLET X, FIELDING CJ, BURLINGAME AL: Site-specific detection and structural characterization of the glycosylation of human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D using HPLC/electrospray mass spectrometry and sequential glycosidase digestion. Protein Sci. (1995) 4:791–803.
   PubMed Web of Science ®Google Scholar
• ZENG C, SPIELMAN Al, VOWELS BR, LEYDEN JJ, BIEMANN K, PRETI G: A human axillary odorant is carried by apolipoprotein D. Proc. Natl Acad. Sci. USA (1996) 93:6626–6630.
   PubMed Web of Science ®Google Scholar
• COLES M, DIERCKS T, MUEHLENWEG B et al.: The solution structure and dynamics of human neutrophil gelatinase-associated lipocalin. j MoL Biol (1999) 289:139–157.
   PubMed Web of Science ®Google Scholar
• FLOWER DR: Beyond the superfamily: thelipocalin receptors. Biochim. Biophys. Acta (2000) 1482:327–336.
   PubMed Web of Science ®Google Scholar
• HVIDBERG V, JACOBSEN C, STRONG RK, COWLAND JB, MOESTRUP SK, BORREGAARD N: The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett. (2005) 579:773–777.
   PubMed Web of Science ®Google Scholar
• YANG J, GOETZ D, LI JY et al.: An iron delivery pathway mediated by a lipocalin. Md. Cell (2002) 10:1045–1056.
   PubMed Web of Science ®Google Scholar
• MORI K, LEE HT, RAPOPORT D et al.: Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J. Clin. Invest. (2005) 115:610–621.
   PubMed Web of Science ®Google Scholar
• WOJNAR P, LECHNER M, MERSCHAK P, REDL B: Molecular cloning of a novel lipocalin-1 interacting human cell membrane receptor using phage display. 1 Biol. Chem. (2001) 276:20206–20212.
   PubMed Web of Science ®Google Scholar
• MICHAUD GA, SALCIUS M, ZHOU F et al.: Analyzing antibody specificity with whole proteome microarrays. Nat. Biotechnol (2003) 21:1509–1512.
   PubMed Web of Science ®Google Scholar
• JAIN RK, BAXTER LT: Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. (1988) 48:7022–7032.
   PubMed Web of Science ®Google Scholar
• SKERRA A: Engineered protein scaffolds for molecular recognition. J. MoL Recognit. (2000) 13:167–187.
   PubMed Web of Science ®Google Scholar
• NYGREN PA, SKERRA A: Binding proteins from alternative scaffolds. Immunol Methods (2004) 290:3–28.
   PubMed Web of Science ®Google Scholar
• SCHLEHUBER S, SKERRA A: Tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant - a so-called `anticalin' - using a molecular random approach. Biophys. Chem. (2002) 96:213–228.
   PubMed Web of Science ®Google Scholar
• COUILLIN I, MAILLET I, VARGAFTIG BB et al.: Arthropod-derived histamine-binding protein prevents murine allergic asthma. J. Immunol (2004) 173:3281–3286.
   PubMed Web of Science ®Google Scholar
• SCHMIDT FS, SKERRA A: The bilin-binding protein of Pieris brassicae. cDNA sequence and regulation of expression reveal distinct features of this insect pigment protein. Eur. J. Biochem. (1994) 219:855–863.
   Google Scholar
• HUBER R, SCHNEIDER M, MAYR I et al.: Molecular structure of the bilin binding protein (BBP) from Pieris brassicae after refinement at 2.0 A resolution. MoL Biol. (1987) 198:499–513.
   Google Scholar
• BESTE G, SCHMIDT FS, STIBORA T,SKERRA A: Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc. Natl. Acad. Sci. USA (1999) 96:1898–1903.
   PubMed Web of Science ®Google Scholar
• SKERRA A: Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties. J. Biotechnol (2001) 74:257–275.
   PubMedGoogle Scholar
• VOSS EW: Fluorescein Hapten: An Immunological Probe. Voss EW (Ed.), CRC Press: Boca Raton, FL, USA (1984).
   Google Scholar
• MCCREERY T: Digoxigenin labeling. Mol Biotechnol (1997) 7:121–124.
   PubMed Web of Science ®Google Scholar
• SCHLEHUBER S, BESTE G, SKERRA A: A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. 1 Mol Biol. (2000) 297:1105–1120.
   PubMed Web of Science ®Google Scholar
• MERCADER JV, SKERRAA: Generation of anticalins with specificity for a nonsymmetric phthalic acid ester. Anal. Biochem. (2002) 308:269–277.
   PubMed Web of Science ®Google Scholar
• KORNDORFER IP, BESTE G, SKERRA A: Crystallographic analysis of an `anticalin' with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region. Proteins (2003) 53:121–129.
   PubMed Web of Science ®Google Scholar
• KORNDORFER IP, SCHLEHUBER S, SKERRA A: Structural mechanism of specific ligand recognition by a lipocalin tailored for the complexation of digoxigenin. J. Mol Biol (2003) 330:385–396.
   PubMed Web of Science ®Google Scholar
• JEFFREY PD, SCHILDBACH JF, CHANG CY, KUSSIE PH, MARGOLIES MN, SHERIFF S: Structure and specificity of the anti-digoxin antibody 40-50.1 Mol Biol (1995) 248:344–360.
   PubMed Web of Science ®Google Scholar
• HAUPTMAN PJ, KELLY RA: Digitalis. Circulation (1999) 99:1265–1270.
   PubMed Web of Science ®Google Scholar
• MCMILLIN GA, OWEN WE, LAMBERT U et al: Comparable effects of DIGIBIND and DigiFab in thirteen digoxin immunoassays. Clin. Chem. (2002) 48:1580–1584.
   PubMed Web of Science ®Google Scholar
• WARD SB, SJOSTROM L, UJHELYI MR: Comparison of the pharmacokinetics and in vivo bioaffinity of DigiTAb versus Digibind. Ther. DrugMonit. (2000) 22:599–607.
   Google Scholar
• LECHAT P, MUDGETT-HUNTER M, MARGOLIES MN, HABER E, SMITH TW: Reversal of lethal digoxin toxicity in guinea pigs using monoclonal antibodies and Fab fragments. J. Pharmacol Exp. Ther. (1984) 229:210–213.
   PubMed Web of Science ®Google Scholar
• KELLY R, PEIM A, WALZ A et ell.: Reversal of digoxin cardiac toxicity by an anticalin (Digical II) in the anaesthetized guinea pig. In: Abstracts of the 'The Physiological Society' Meeting. University College Cork, Ireland (2004).
   Google Scholar
• GOODMAN DS: Plasma retinol-bindingprotein. In: The Retinoids. Sporn R, Goodman D (Eds), Academic Press, Orlando, FL, USA (1984):41–87.
   Google Scholar
• AXELSSON L, BERGENFELDT M, OHLSSON K: Studies of the release and turnover of a human neutrophil lipocalin. Scand. J. Clin. Lab. Invest. (1995) 55:577–588.
   PubMed Web of Science ®Google Scholar
• AKERSTROM B, LOGDBERG L, BERGGARD T, OSMARK P, LINDQVIST A: al-Microglobulin: a yellow-brown lipocalin. Biochim. Biophys. Acta (2000) 1482:172–184.
   PubMed Web of Science ®Google Scholar
• MISHRA J, MORI K, MA Q et ell.: Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol. (2004) 15:3073–3082.
   Google Scholar
• WALSH G: Biopharmaceutical benchmarks- 2003. Nat. BiotechnoL (2003) 21:865–870.
   PubMed Web of Science ®Google Scholar
• VOGT M, SKERRA A: Construction of an artificial receptor protein ('anticalin') based on the human apolipoprotein D. Chembiochem. (2004) 5:191–199.
   PubMed Web of Science ®Google Scholar
• ALLISON JP, KRUMMEL MF: The Yin and Yang of T cell costimulation. Science (1995) 270:932–933.
   PubMed Web of Science ®Google Scholar
• DAVIS SJ, IKEMIZU S, EVANS EJ, FUGGER L, BAKKER TR, VAN DER MERWE PA: The nature of molecular recognition by T cells. Nat. Immunol. (2003) 4:217–224.
   PubMed Web of Science ®Google Scholar
• LEACH DR, KRUMMEL MF, ALLISON JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 271: 1734-1736.
   Google Scholar
• KELER T, HALK E, VITALE L et al.: Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J. Immunol. (2003) 171:6251–6259.
   PubMed Web of Science ®Google Scholar
• PHAN GQ, YANG JC, SHERRY RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA (2003) 100:8372–8377.
   PubMed Web of Science ®Google Scholar
• CAMACHO LH, RIBAS A, GLASPY JAet al.: Phase I clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid 1461 malignancies. J. Clin. Oncol. (Meeting Abstracts) (2004) 22:Abstract #2505.
   Google Scholar
• MANS BJ, NEITZ AW: Adaptation of ticks to a blood-feeding environment: evolution from a functional perspective. Insect Biochem. MoL Biol. (2004) 34:1–17.
   PubMed Web of Science ®Google Scholar
• RIBEIRO JM, ANDERSEN J, SILVA-NETO MA, PHAIVI VM, GARFIELD MK, VALENZUELA JG: Exploring the sialome of the blood-sucking bug Rhodnius prolixus. Insect Biochem. MoL Biol. (2004) 34:61–79.
   PubMedGoogle Scholar
• PAESEN GC, ADAMS PL, HARLOS K, NUTTALL PA, STUART DI: Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. Mo/. Cell (1999) 3:661–671.
   PubMed Web of Science ®Google Scholar
• KEMP DH, BOURNE A: Boophilus microplus: the effect of histamine on the attachment of cattle-tick larvae-studies in vivo and in vitro. Parasitology (1980) 80:487–496.
   PubMed Web of Science ®Google Scholar
• NOESKE-JUNGBLUT C, HAENDLER B, DONNER P, ALAGON A, POSSANI L, SCHLEUNING WD: Triabin, a highly potent exosite inhibitor of thrombin. Biol. Chem. (1995) 270:28629–28634.
   Web of Science ®Google Scholar
• FUENTES-PRIOR P, NOESKE-JUNGBLUT C, DONNER P, SCHLEUNING WD, HUBER R, BODE W: Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibitor derived from a triatomine bug. Proc. Natl. Acad. Sci. USA (1997) 94:11845–11850.
   PubMed Web of Science ®Google Scholar
• GLUSA E, BRETSCHNEIDER E, DAUM J, NOESKE-JUNGBLUT C: Inhibition of thrombin-mediated cellular effects by triabin, a highly potent anion-binding exosite thrombin inhibitor. Thromb. Haemost. (1997) 77:1196–1200.
   PubMed Web of Science ®Google Scholar
• FRANCISCHETTI IM, RIBEIRO JM, CHAMPAGNE D, ANDERSEN J: Purification, cloning, expression, and mechanism of action of a novel platelet aggregation inhibitor from the salivary gland of the blood-sucking bug, Rhodnius prolixus. Biol. Chem. (2000) 275:12639–12650.
   Web of Science ®Google Scholar
• MONTFORT WR, WEICHSEL A. ANDERSEN JF: Nitrophorins and related antihemostatic lipocalins from Rhodnius prolixus and other blood-sucking arthropods. Biochim. Biophys. Acta (2000) 1482:110–118.
   PubMed Web of Science ®Google Scholar
• KELLER PM, WAXMAN L, ARNOLD BA, SCHULTZ LD, CONDRA C, CONNOLLY TM: Cloning of the cDNA and expression of moubatin, an inhibitor of platelet aggregation. Biol. Chem. (1993) 268:5450–5456.
   Web of Science ®Google Scholar
• WAXMAN L, CONNOLLY TM: Isolation of an inhibitor selective for collagen-stimulated platelet aggregation from the soft tick Ornithodoros moubata. j Biol. Chem. (1993) 268:5445–5449.
   PubMed Web of Science ®Google Scholar
• NOESKE-JUNGBLUT C, KRATZSCHMAR J, HAENDLER Bet aL: An inhibitor of collagen-induced platelet aggregation from the saliva of Triatoma pallidipennis. J. Biol. Chem. (1994) 269:5050–5053.
   PubMed Web of Science ®Google Scholar
• ANDERSEN JF, FRANCISCHETTI IM, VALENZUELA JG, SCHUCK P, RIBEIRO JM: Inhibition of hemostasis by a high affinity biogenic amine-binding protein from the saliva of a blood-feeding insect. J. Biol. Chem. (2003) 278:4611–4617.
   PubMed Web of Science ®Google Scholar
• BRAUN V, KILLMANN H: Bacterial solutions to the iron-supply problem. Trends Biochem. Sci. (1999) 24:104–109.
   PubMed Web of Science ®Google Scholar
• RATLEDGE C, DOVER LG: Iron metabolism in pathogenic bacteria. Annu. Rev. MicrobioL (2000) 54:881–941.
   PubMed Web of Science ®Google Scholar
• FLOWER DR: Benzon Symposium no. 50: The lipocalin protein superfamily. Targets (2003) 2:235–236.
   Google Scholar
• SAMAMA MM, GEROTZIAFAS GT: Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb. Res. (2003) 109:1–11.
   PubMed Web of Science ®Google Scholar
• MUHSIN M, GRAHAM J, KIRKPATRICK P: Bevacizumab. Nat. Rev. Drug Discov. (2004) 3:995–996.
   PubMed Web of Science ®Google Scholar
• BONNEFOY A, VERMYLEN J, HOYLAERTS MF: Inhibition of von Willebrand factor-GPIb/IX/V interactions as a strategy to prevent arterial thrombosis. Expert Rev. Cardiovasc. Ther. (2003) 1:257–269.
   PubMedGoogle Scholar
• CAUWENBERGHS N, MEIRING M, VAUTERIN S et al.: Antithrombotic effect of platelet glycoprotein lb-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler. Thromb. Vasc. Biol. (2000) 20:1347–1353.
   PubMed Web of Science ®Google Scholar
• OSBORN BL, OLSEN HS, NARDELLI B et al.: Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-a fusion protein in cynomolgus monkeys. J. PharmacoL Exp. Ther. (2002) 303:540–548.
   PubMed Web of Science ®Google Scholar
• HARRIS JM, CHESS RB: Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. (2003) 2:214–221.
   PubMed Web of Science ®Google Scholar
• SCHELLEKENS H: Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. (2002) 24:1720–1740.
   PubMed Web of Science ®Google Scholar
• PASTAN I: Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer ImmunoL Immunother. (2003) 52:338–341.
   PubMed Web of Science ®Google Scholar
• BRINKMANN U, PASTAN I: Immunotoxins against cancer. Biochim. Biophys. Acta (1994) 1198:27–45.
   PubMed Web of Science ®Google Scholar
• CARTER P: Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer (2001)1:118–129.
   PubMed Web of Science ®Google Scholar
• GILES F, ESTEY E, O'BRIEN S: Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer (2003) 98:2095–2104.
   PubMed Web of Science ®Google Scholar
• GILES FJ: Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Expert Rev. Anticancer Ther. (2002) 2:630–640.
   PubMedGoogle Scholar
• http://www.gsk.com GlaxoSmithKline website.
   Google Scholar
• http://www.protherics.com Protherics website.
   Google Scholar
• http://www.pieris.biz PRIERIS Proteolab AG website.
   Google Scholar
• http://www.medarex.com Medarex, Inc. website.
   Google Scholar
• http://www.evolutec.co.uk Evolutec group plc website.
   Google Scholar
• http://www.paion.de Paion AG website.
   Google Scholar
• http://www.gene.com Genentech, Inc. website.
   Google Scholar
• SCHLEHUBER S, SKERRA A: W003029463 (2002).
   Google Scholar